サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1757879

チロシンキナーゼ阻害剤の世界市場

Tyrosine Kinase Inhibitors

出版日
ページ情報
英文 290 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.64円
チロシンキナーゼ阻害剤の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 290 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

チロシンキナーゼ阻害剤の世界市場は2030年までに782億米ドルに達する見込み

2024年に529億米ドルと推定されるチロシンキナーゼ阻害剤の世界市場は、2024～2030年の分析期間においてCAGR 6.7%で成長し、2030年には782億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるBCR-ABLは、CAGR 8.5%を記録し、分析期間終了までに408億米ドルに達すると予想されます。上皮成長因子受容体セグメントの成長率は、分析期間中CAGR 4.6%と推定されます。

米国市場は144億米ドルと推定、中国はCAGR10.9%で成長予測

米国のチロシンキナーゼ阻害剤市場は、2024年に144億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに165億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.2%と6.6%と予測されています。欧州では、ドイツがCAGR 4.5%で成長すると予測されています。

世界の「チロシンキナーゼ阻害剤」市場- 主要動向と促進要因のまとめ

チロシンキナーゼ阻害剤ががん標的治療の礎になりつつあるのはなぜか？

チロシンキナーゼ阻害剤（TKI）の登場は、広範な化学療法から分子標的に合わせた精密医療へとパラダイムをシフトさせることで、がん治療に革命をもたらしました。これらの低分子薬剤は、増殖、分化、アポトーシスなどの重要な細胞内プロセスを制御する酵素であるチロシンキナーゼの活性を阻害することによって作用します。これらの酵素が変異したり、活性が過剰になったりすると、がんに特徴的な制御不能な増殖の一因となります。慢性骨髄性白血病（CML）におけるBCR-ABL融合体の発見と、FDAに初めて承認されたTKIであるイマチニブの成功は、さまざまながん種における同様の分子標的に関する研究開発の波に火をつけた。今日、TKIは非小細胞肺がん（NSCLC）、消化管間質腫瘍（GIST）、腎細胞がん、乳がんなどの悪性腫瘍の治療に不可欠な薬剤となっています。その利点は、特異性が高いこと、経口投与が可能であること、従来の治療法に比べて生存率が向上することです。発がん経路の理解が深まるにつれ、TKIの役割は併用療法や術後補助療法へと拡大し、現代腫瘍学の要となっています。

ゲノミクスとバイオマーカー研究の進歩はTKI開発をどのように促進しているか？

ゲノミクスとコンパニオン診断の進歩は、正確な患者選択を可能にすることで、TKIの開発と応用を大きく促進しました。包括的なゲノム・プロファイリングにより、EGFR、ALK、ROS1、HER2、RETなどの実用的な変異の同定が可能になりました。このため、これらの特定の変異を標的とした次世代TKIのFDA承認が急増し、より個別化された効果的な治療が提供されています。例えば、オシメルチニブはEGFR変異NSCLCに対して顕著な有効性を示し、アレクチニブは中枢神経系への活性と低毒性プロファイルにより、ALK陽性肺がんに対する優先的治療薬となっています。これと並行して、リキッドバイオプシーや次世代シーケンサー（NGS）の利用により、病勢進行や耐性メカニズムのリアルタイムモニタリングが向上しています。これらのツールはまた、治療効果を維持しながら副作用を軽減するための適応的投与戦略の開発を促進しています。さらに、アロステリック阻害剤、不可逆的結合剤、デュアルターゲット剤などの新規製剤が臨床研究中であり、耐性経路を克服し、腫瘍微小環境における薬剤の浸透を改善することを目指しています。

薬剤耐性と有害事象はTKI治療の勢いを削ぐか？

TKIはその有望性にもかかわらず、限界がないわけではなく、その最たるものが後天性耐性と標的外毒性です。がん細胞はしばしば二次的変異を起こしたり、代替シグナル伝達経路を活性化したりするため、最初のTKI治療が時間の経過とともに効かなくなります。例えば、EGFRのT790M変異やBCR-ABLのゲートキーパー変異は、第一世代のTKIを損なう可能性があり、第二世代、第三世代の薬剤の開発が必要となります。さらに、TKIの長期使用は、肝毒性、心毒性、皮膚科学的問題などの重大な副作用を伴い、患者のコンプライアンスに影響を及ぼす可能性があります。継続的な分子モニタリングと潜在的な治療調節の必要性は、治療レジメンに複雑さを加えます。さらに、高い治療費と低リソース環境での限られたアクセスは、普及の大きな障壁となっています。しかし、現在進行中のTKIと免疫チェックポイント阻害剤、モノクローナル抗体、または化学療法薬との併用は、耐性を回避し、有効性を高めるのに役立つ可能性があります。また、複数の経路を同時に標的とすることができる汎キナーゼ阻害剤の開発も進められており、エスケープメカニズムの可能性を減らし、治療適応をがん領域だけでなく炎症性疾患や線維症などの領域にも広げています。

チロシンキナーゼ阻害剤の世界の需要の持続的成長の背景は？

チロシンキナーゼ阻害剤市場の成長は、臨床実践、研究パイプライン、患者の期待を形成するいくつかの要因によって牽引されています。最も大きな要因の一つは、特定可能なチロシンキナーゼ変異を持つがんの世界の発生率の増加であり、特に環境的なリスク要因が強まっている急速な都市化地域におけるものです。次に、バイオマーカーに基づく診断法に対する認識と利用可能性の高まりが、早期発見と適切な治療の選択を改善し、第一線の治療オプションとしてのTKIに対する需要を促進しています。技術面では、バイオファーマ企業の強固な研究開発パイプラインにより、安全性と有効性のプロファイルが改善された新規TKIが着実に開発されており、多くの場合、希少な変異や以前は治療不可能であった変異に対して調整されています。さらに、臨床ガイドラインの進化により、TKIが早期治療に組み込まれ、維持療法やネオアジュバント療法での使用が拡大しています。もう一つの重要な要因は、TKIが満足する経口、外来投与治療への嗜好の高まりであり、これによって入院費用が削減され、患者のQOLが向上しています。最後に、特に中国、インド、ブラジルのような国々では、保険適用が拡大し、国の償還リストに組み込まれたことで、市場浸透が加速しています。このように、疫学的、臨床的、技術的、政策的な影響が組み合わさることで、世界市場全体で旺盛な需要が維持されています。

セグメント

タイプ（BCR-ABL、上皮成長因子受容体、血管内皮成長因子受容体、その他のタイプ）、アプリケーション（慢性骨髄性白血病、肺がん、乳がん、腎細胞がん、その他のアプリケーション）

調査対象企業の例（注目の44社）

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35935

Global Tyrosine Kinase Inhibitors Market to Reach US$78.2 Billion by 2030

The global market for Tyrosine Kinase Inhibitors estimated at US$52.9 Billion in the year 2024, is expected to reach US$78.2 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. BCR-ABL, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$40.8 Billion by the end of the analysis period. Growth in the Epidermal Growth Factor Receptor segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$14.4 Billion While China is Forecast to Grow at 10.9% CAGR

The Tyrosine Kinase Inhibitors market in the U.S. is estimated at US$14.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.5 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global "Tyrosine Kinase Inhibitors" Market - Key Trends & Drivers Summarized

Why Are Tyrosine Kinase Inhibitors Becoming The Cornerstone Of Targeted Cancer Therapy?

The emergence of tyrosine kinase inhibitors (TKIs) has revolutionized cancer treatment by shifting the paradigm from broad-spectrum chemotherapy to precision medicine tailored to molecular targets. These small-molecule drugs work by blocking the activity of tyrosine kinases-enzymes that regulate critical cellular processes including growth, differentiation, and apoptosis. When these enzymes mutate or become overactive, they contribute to the uncontrolled proliferation characteristic of cancers. The discovery of BCR-ABL fusion in chronic myeloid leukemia (CML) and the success of Imatinib, the first FDA-approved TKI, ignited a wave of research and development into similar molecular targets across different cancer types. Today, TKIs are indispensable in the treatment of malignancies like non-small cell lung cancer (NSCLC), gastrointestinal stromal tumors (GIST), renal cell carcinoma, and breast cancer. Their advantage lies in high specificity, oral administration, and improved survival outcomes compared to conventional treatments. As our understanding of oncogenic pathways deepens, the role of TKIs is expanding into combination therapies and adjuvant settings, making them a cornerstone of modern oncology.

How Are Advancements In Genomics And Biomarker Research Fueling TKI Development?

The advancement of genomics and companion diagnostics has significantly enhanced the development and application of TKIs by enabling precise patient selection. Comprehensive genomic profiling allows for the identification of actionable mutations such as EGFR, ALK, ROS1, HER2, and RET, among others. This has led to a surge in FDA approvals of next-generation TKIs designed to target these specific alterations, offering more personalized and effective treatments. For instance, Osimertinib has shown significant efficacy against EGFR-mutated NSCLC, while Alectinib has become the preferred therapy for ALK-positive lung cancers due to its CNS activity and lower toxicity profile. In parallel, the use of liquid biopsies and next-generation sequencing (NGS) is improving real-time monitoring of disease progression and resistance mechanisms. These tools are also fostering the development of adaptive dosing strategies to mitigate side effects while maintaining therapeutic efficacy. Furthermore, novel formulations such as allosteric inhibitors, irreversible binders, and dual-targeted agents are under clinical investigation, aiming to overcome resistance pathways and improve drug penetration in tumor microenvironments.

Could Drug Resistance And Adverse Events Derail The Momentum Of TKI Therapies?

Despite their promise, TKIs are not without limitations-chief among them being acquired resistance and off-target toxicity. Cancer cells often develop secondary mutations or activate alternative signaling pathways, rendering initial TKI treatments ineffective over time. For example, the T790M mutation in EGFR or the gatekeeper mutation in BCR-ABL can compromise first-generation TKIs, necessitating the development of second- and third-generation agents. Additionally, long-term use of TKIs is associated with significant side effects, including hepatotoxicity, cardiotoxicity, and dermatological issues, which can affect patient compliance. The need for continuous molecular monitoring and potential therapy adjustments adds complexity to treatment regimens. Moreover, high treatment costs and limited access in low-resource settings present substantial barriers to widespread adoption. However, ongoing efforts to combine TKIs with immune checkpoint inhibitors, monoclonal antibodies, or chemotherapeutics may help to circumvent resistance and enhance efficacy. There is also a push toward the development of pan-kinase inhibitors that can simultaneously target multiple pathways, thus reducing the likelihood of escape mechanisms and expanding therapeutic indications beyond oncology into areas like inflammatory diseases and fibrosis.

What’s Behind The Sustained Growth In Global Demand For Tyrosine Kinase Inhibitors?

The growth in the tyrosine kinase inhibitors market is driven by several factors shaping clinical practices, research pipelines, and patient expectations. One of the foremost drivers is the increasing global incidence of cancers with identifiable tyrosine kinase mutations, particularly in rapidly urbanizing regions where environmental risk factors are intensifying. Secondly, rising awareness and availability of biomarker-based diagnostics have improved early detection and appropriate therapy alignment, propelling the demand for TKIs as front-line treatment options. On the technological front, robust R&D pipelines from biopharma companies are yielding a steady influx of novel TKIs with improved safety and efficacy profiles, often tailored for rare or previously untreatable mutations. Furthermore, evolving clinical guidelines are incorporating TKIs into earlier lines of therapy and expanding their use in maintenance and neoadjuvant settings. Another key factor is the growing preference for oral, outpatient-administered treatments, which TKIs satisfy, thereby reducing hospitalization costs and improving quality of life for patients. Lastly, expanded insurance coverage and inclusion in national reimbursement lists, especially in countries like China, India, and Brazil, are accelerating market penetration. This combination of epidemiological, clinical, technological, and policy-driven influences is sustaining strong demand across global markets.

SCOPE OF STUDY:

The report analyzes the Tyrosine Kinase Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor, Other Types); Application (Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Tyrosine Kinase Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Cancer Incidence Propels Demand for Targeted Therapies
    • FDA Breakthrough Therapy Designations Strengthen Business Case for TKIs
    • Expansion of Companion Diagnostics Drives Adoption of Personalized Oncology
    • Growing Investment in Precision Medicine Accelerates Pipeline Growth
    • Favorable Reimbursement Policies in Developed Markets Sustain Uptake
    • Emerging Clinical Evidence Throws the Spotlight on Multi-Target TKIs
    • Increasing Availability of Generic TKIs Expands Patient Access in Developing Markets
    • Technological Advancements in Drug Delivery Spur Innovation in Oral Formulations
    • Strategic Collaborations and Licensing Agreements Propel Market Growth
    • Rising Demand for Minimal Side-Effect Therapies Generates Opportunities
    • Post-Patent Expiry Dynamics Create Competitive Pricing Pressures
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tyrosine Kinase Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for BCR-ABL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for BCR-ABL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for BCR-ABL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Epidermal Growth Factor Receptor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Epidermal Growth Factor Receptor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vascular Endothelial Growth Factor Receptor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vascular Endothelial Growth Factor Receptor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Vascular Endothelial Growth Factor Receptor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Chronic Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Chronic Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Chronic Myeloid Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Renal Cell Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Renal Cell Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Renal Cell Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Tyrosine Kinase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Tyrosine Kinase Inhibitors by Type - BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Tyrosine Kinase Inhibitors by Type - Percentage Breakdown of Value Sales for BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor and Other Types for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Tyrosine Kinase Inhibitors by Application - Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Tyrosine Kinase Inhibitors by Application - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION